Back to first-pass browser

First-pass extracted concept

first-generation AAV vectors

Candidate: concept label1 source documents3 linked claims
Jump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Evidence Snippets

it has become increasingly clear that the first generation of AAV vectors is less than optimal since in most, if not all, cases, exceedingly high doses are needed to achieve clinical efficacy
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1limitationsupports2026Source 1DOIPubMed

First-generation AAV vectors are less than optimal because exceedingly high doses are needed to achieve clinical efficacy in most if not all cases.

Claim 2safetysupports2026Source 1DOIPubMed

At least 21 patients have died in the context described for first-generation AAV vector use.

Claim 3safetysupports2026Source 1DOIPubMed

Use of first-generation AAV vectors at high doses has been associated with serious adverse events in some patients.